Last $0.16 USD
Change Today +0.005 / 3.25%
Volume 60.7K
RGRX On Other Exchanges
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

regenerx biopharmaceuticals (RGRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/21/14 - $0.27
52 Week Low
08/28/14 - $0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

regenerx biopharmaceuticals (RGRX) Related Businessweek News

No Related Businessweek News Found

regenerx biopharmaceuticals (RGRX) Details

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of molecules for tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tß4), an amino acid peptide. It develops RGN-259, a topical eye drops that that has completed the Phase IIa exploratory clinical trials and for the regeneration of corneal tissues damaged by injury, disease, or other pathology; and RGN-352, an injectable formulation, which has completed Phase I clinical trials and is intended to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications treated by systemic administration. The company also develops RGN-137, a topical gel that is in Phase II clinical trials and intended for the treatment of epidermolysis bullosa, pressure ulcers, and venous stasis ulcers. It also seeks to identify and evaluate Tß4 peptide fragments and derivatives for use as components in cosmeceutical and consumer products. RegeneRx Biopharmaceuticals, Inc. has a strategic partnership with Defiante Farmaceutica S.A. for the development and marketing of RGN-137 and RGN-352 for specified indications in Europe and other countries. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

5 Employees
Last Reported Date: 04/4/14
Founded in 1982

regenerx biopharmaceuticals (RGRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $65.0K
Compensation as of Fiscal Year 2013.

regenerx biopharmaceuticals (RGRX) Key Developments

Regenerx Biopharmaceuticals and G-treeBNT Co., Ltd. Partner to Develop RGN-259 in the US for Ophthalmic Indications

RegeneRx Biopharmaceuticals reported the launch of an agreement to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the US in partnership with G-treeBNT Co. This joint venture (JV) agreement allows G-treeBNT to conduct and fund all clinical trials and product development through approval of a new drug application (NDA). Under the license agreement, RegeneRx granted the JV an exclusive, royalty-bearing license to market and sell it's RGN-259 in the US as well as contributed all of its non-clinical and clinical data generated to date. G-treeBNT will hold a majority equity stake in the JV that will increase as it successfully reaches development milestones. In addition, RegeneRx has the right to approve key product licensing, mergers or acquisitions; receive a total of USD 1 million in two tranches, as well as royalties ranging from high single digits to low double digits, depending on medical indications approved and if the JV's ophthalmic product candidates are commercialised internally or through a third party; retain a significant equity position in the JV; and will not be required to provide any funding for the venture.

Regenerx Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Regenerx Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

RegeneRx Biopharmaceuticals Reports Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model

RegeneRx Biopharmaceuticals Inc. reported new published data demonstrating that Thymosin beta 4 (TB4) can be used effectively to prevent or reduce heart failure. In a standard murine model of pulmonary hypertension (induced by a toxic plant alkaloid) that causes compensatory right heart hypertrophy, TB4 significantly reduced the systolic pressure and right ventricular hypertrophy when compared to animals that were not treated with TB4. This study was reported in the scientific journal PLOS ONE, OI:10.1371/journal.pone.0110598 November 20, 2014. The company announced that the study provides additional evidence that TB4 could be used as a vasculoprotective agent for the treatment of pulmonary hypertension-induced heart failure and confirms other independent studies showing the reduction of damage and improvement of function in both acute and sub-chronic cardiac models.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGRX:US $0.16 USD +0.005

RGRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RGRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERX BIOPHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at